ArticleMedicina (Kaunas, Lithuania)2026
Clinicopathological Predictors of Pathological Complete Response in HER2-Positive Breast Cancer Treated with Pertuzumab-Based Neoadjuvant Therapy: A Multicenter Real-World Study.
Fatih Yıldız, Berkan Karabuga, Salih Karatlı, Merve Yalınkılıç, İlknur Deliktas Onur, Ece Bilgic Koylu, Sıla Soylu Kocoğlu, Emrah Eraslan, Aysegül Ilhan Gülesen, Erkan Erdur and 4 more
Abstract readMulticenter Study
In one paragraphArticle in Medicina (Kaunas, Lithuania), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
14 authors.
Fatih YıldızDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.
Berkan KarabugaDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.ORCID 0000-0001-5357-7610 Merve YalınkılıçDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.
İlknur Deliktas OnurDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.ORCID 0000-0001-9884-5789 Ece Bilgic KoyluDepartment of Medical Oncology, Ankara University Faculty of Medicine, Ankara 06050, Turkey.
Sıla Soylu KocoğluDepartment of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, Turkey.
Emrah EraslanDepartment of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara 06200, Turkey.
Aysegül Ilhan GülesenDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.ORCID 0000-0002-0333-1388 Erkan ErdurDepartment of Internal Medicine, Division of Medical Oncology, Gazi Yaşargil Training and Research Hospital, Diyarbakir 21070, Turkey.
Ozgen Ahmet YildirimDepartment of Medical Oncology, Ankara Etlik City Hospital, Ankara 06170, Turkey.ORCID 0000-0002-4139-067X Fatih GurlerDepartment of Medical Oncology, Gazi University Faculty of Medicine, Ankara 06560, Turkey.ORCID 0000-0003-0023-5793 Hatime Arzu YasarDepartment of Medical Oncology, Ankara University Faculty of Medicine, Ankara 06050, Turkey.ORCID 0000-0002-0545-1383 Ferit AslanMedical Oncology, Yüksek İhtisas University Affiliated Medicalpark Ankara Batıkent Hospital, Ankara 06370, Turkey.ORCID 0000-0002-9153-6921 Funding
No grant is acknowledged in the PubMed record.
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
Antibodies, Monoclonal, HumanizedBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesNeoadjuvant TherapyAdultAgedFemaleHumansLogistic ModelsMiddle AgedPathologic Complete ResponseRetrospective StudiesTreatment OutcomeAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabHER2-positive breast cancerneoadjuvant therapypathological complete responsepertuzumabsystemic inflammatory biomarkers
Identifiers
PMID42075632
PMCPMC13117290
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390